Division of Adolescent and Young Adult Medicine, Boston Children's Hospital, 333 Longwood Ave., #634, Boston, MA 02115, USA ; Department of Social and Behavioral Sciences, Harvard School of Public Health, Boston, MA, USA.
Group Health Research Institute, Seattle, WA, USA ; Department of Health Services Research, University of Washington, School of Public Health, Seattle, WA, USA.
J Eat Disord. 2013 Oct 21;1:40. doi: 10.1186/2050-2974-1-40. eCollection 2013.
Abuse of over-the-counter (OTC) products, such as diet pills and laxatives, for weight control by adolescents is well-documented and can precipitate serious medical conditions. Yet only a small percentage of youth with disordered weight control behaviors receive treatment. The objective of this study was to examine how often clinicians communicate with youth with symptoms consistent with abuse of OTC products for weight control about possible use of these products. We used electronic medical records and administrative claims for services for 53,229 12 to 17 year old patients receiving care from an integrated health system in the U.S. Northwest from August 2007 to December 2010. We examined electronic text of clinical notes to identify encounters in which the clinician noted one of 10 metabolic conditions potentially associated with abuse of OTC products (diet pills, laxatives, diuretics, ipecac, orlistat, and alli®) for weight control and then assessed whether clinicians noted communication with adolescent patients about possible use of OTC products for weight control.
We identified 130 (0.2% of sample) patients with clinical notes indicating one or more of the metabolic conditions. In clinical notes for only four (3.1%) of these patients did clinicians document suspicion or communication about possible abuse of the OTC products. All four had a previous eating disorder diagnosis. In the 12 months subsequent to the clinical encounter in which a metabolic disturbance was identified, medical notes for only three (2.3%) of the 130 patients indicated clinician suspicion or communication about possible abuse of these products or an eating disorder.
Clinicians are missing a critical window of opportunity to query adolescents when presenting with suspicious metabolic disturbances about possible abuse of OTC products for weight control. Clinicians may need more training to detect OTC product abuse, and electronic medical records should prompt more thorough enquiry.
青少年滥用非处方(OTC)产品,如减肥药和泻药来控制体重,这种情况已被充分记录,并可能引发严重的健康问题。然而,只有一小部分有不当体重控制行为的青少年接受治疗。本研究的目的是调查临床医生在多大程度上与有疑似滥用 OTC 产品控制体重症状的青少年交流这些产品的潜在使用情况。我们使用了美国西北一个综合健康系统在 2007 年 8 月至 2010 年 12 月期间为 53229 名 12 至 17 岁患者提供的电子病历和行政服务记录。我们检查了临床记录的电子文本,以识别临床医生记录有十种代谢紊乱之一的就诊记录,这些紊乱可能与滥用 OTC 产品(减肥药、泻药、利尿剂、吐根、奥利司他和 alli®)控制体重有关,然后评估临床医生是否记录了与青少年患者关于可能使用 OTC 产品控制体重的交流。
我们在有临床记录表明有一项或多项代谢紊乱的 130 名患者中识别出 130 名(占样本的 0.2%)患者。在这四名患者的临床记录中,只有四名临床医生记录了对可能滥用 OTC 产品的怀疑或交流。这四名患者都有以前的饮食失调诊断。在识别出代谢紊乱的临床就诊后的 12 个月内,只有 130 名患者中的 3 名(2.3%)的医疗记录表明临床医生怀疑或交流了可能滥用这些产品或饮食失调。
临床医生在出现可疑代谢紊乱时,错过了询问青少年可能滥用 OTC 产品控制体重的关键机会窗口。临床医生可能需要更多的培训来发现 OTC 产品滥用,电子病历应该提示更彻底的询问。